Erika Paula Machado Peixoto

Erika Paula Machado Peixoto

Auto-generated profile, based on publicly available information

Erika Paula Machado Peixoto

Affiliation Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2020 in Science Advances
Verified
Journal Article
Open access
ARAramys Silva Reis
Aramys Silva Reis
RBRenato Barboza
Renato Barboza
OMOscar Murillo
Oscar Murillo
ABAndré Barateiro
André Barateiro
EPErika P. M. Peixoto
Erika P. M. Peixoto
Claudio Romero Farias MarinhoClaudio Romero Farias Marinho
Claudio Romero Farias Marinho
IL-1 axis activation during placental malaria induces poor pregnancy outcomes that are obliterated after treatment with Anakinra.

29 April 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
JDJamille G. Dombrowski
Jamille G. Dombrowski
ABAndré Barateiro
André Barateiro
EPErika Paula Machado Peixoto
Erika Paula Machado Peixoto
ABAndré Boler Cláudio da Silva Barros
André Boler Cláudio da Silva Barros
RMRodrigo Medeiros Martorano
Rodrigo Medeiros Martorano
Claudio Romero Farias MarinhoClaudio Romero Farias Marinho
Claudio Romero Farias Marinho
Background: Malaria in Brazil represents one of the highest percentages of Latin America cases, where approximately 84% of infections are attributed toPlasmodium(P.) vivax. Despite the high incidence, many aspects of gestational malaria resulting fromP.vivaxinfections remain poorly studied. As such, we aimed to evaluate the consequences ofP.vivaxinfections during gestation on the health of mothers and their neonates in an endemic area of the Amazon.Methods and findings: We have conducted an observational cohort study in Brazilian Amazon between January 2013 and April 2015. 600 pregnant women were enrolled and followed until delivery. After applying exclusion criteria, 329 mother-child pairs were included in the analysis. Clinical data regarding maternal infection, newborn’s anthropometric measures, placental histopathological characteristics, and angiogenic and inflammatory factors were evaluated. The presence of plasma IgG against theP.vivax(Pv) MSP119protein was used as marker of exposure and possible associations with pregnancy outcomes were analyzed. Multivariate logistic regression analysis revealed thatP.vivaxinfections during the first trimester of pregnancy are associated with adverse gestational outcomes such as premature birth (adjusted odds ratio [aOR] 8.12, 95% confidence interval [95%CI] 2.69–24.54,p< 0.0001) and reduced head circumference (aOR 3.58, 95%CI 1.29–9.97,p= 0.01). Histopathology analysis showed marked differences between placentas fromP.vivax-infected and non-infected pregnant women, especially regarding placental monocytes infiltrate. Placental levels of vasomodulatory factors such as angiopoietin-2 (ANG-2) and complement proteins such as C5a were also altered at delivery. Plasma levels of anti-PvMSP119IgG in infected pregnant women were shown to be a reliable exposure marker; yet, with no association with improved pregnancy outcomes.Conclusions: This study indicates thatP.vivaxmalaria during the first trimester of pregnancy represents a higher likelihood of subsequent poor pregnancy outcomes associated with marked placental histologic modification and angiogenic/inflammatory imbalance. Additionally, our findings support the idea that antibodies against PvMSP119are not protective against poor pregnancy outcomes induced byP.vivaxinfections.

3 May 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
JDJamille G. Dombrowski
Jamille G. Dombrowski
RMRodrigo Medeiros Martorano
Rodrigo Medeiros Martorano
FLAVIA AFONSO LIMAFLAVIA AFONSO LIMA
FLAVIA AFONSO LIMA
CBCarla Letícia Bandeira
Carla Letícia Bandeira
OMOscar Murillo
Oscar Murillo
Claudio Romero Farias MarinhoClaudio Romero Farias Marinho
Claudio Romero Farias Marinho
Having malaria during pregnancy, especially falciparum malaria, can be devastating and fulminant, leading to high mortality rates for both mother and fetus, with approximately 125 million pregnancies at risk of infection each year.1 Infected erythrocytes accumulate and sequester in the placental intervillous space, causing placental histopathologic changes that trigger an exacerbated inflammatory response that is highly detrimental.2 A heightened inflammatory response perturbs the maternal-fetal interface and impairs critical placental functions. Therefore, maternal malaria is associated with major complications among fetuses and newborns, including being the primary cause of low birth weight, intrauterine growth retardation, abortion, stillbirth, premature delivery, and fetal death in malaria-endemic countries.1 In addition, in utero exposure to malaria parasites has been associated with a decreased head circumference (HC) among fetuses and newborns, a proportional decrease in size as an outcome of the intrauterine growth retardation.3-6